{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-089004","form_type":"8-K","ticker":"VCNX","cik":"0001205922","company_name":"VACCINEX, INC.","filed_at":"2023-04-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.170801+00:00","generated_at":"2026-06-17T06:48:39.682704+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Vaccinex raises ~$2.04M in private placement at $0.41/share; insider participation","bullets":["Sold 4,975,608 shares at $0.41/share for gross proceeds of ~$2.04 million to three investors, including affiliates of CEO and chairman.","Proceeds will fund development and clinical trials of lead drug candidate pepinemab in cancer and neurodegenerative disease, plus working capital.","FCMI Parent Co., controlled by chairman Albert D. Friedberg, committed to purchase up to an additional $2.96 million of shares on or before May 15, 2023.","Albert Friedberg covenanted to vote his shares in excess of 40% proportionately with other holders; registration rights granted to non-affiliated investor.","Shares issued in private placement exempt from registration under Section 4(a)(2) of Securities Act and Rule 506 of Regulation D."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-089004","json":"https://secwatch.observer/filing/0001193125-23-089004.json","markdown":"https://secwatch.observer/filing/0001193125-23-089004.md","text":"https://secwatch.observer/filing/0001193125-23-089004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1205922/000119312523089004/0001193125-23-089004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1205922/000119312523089004/d462228d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T06:48:39.682704+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"40392f61472f43238daa4ccd47c6a497d6821a38","claim":"VACCINEX, INC. entered into Stock Purchase Agreement with Vaccinex (Rochester), L.L.C. and FCMI Parent Co. valued at aggregate gross proceeds of approximately $2.04 million (effective 2023-03-30).","evidence_excerpt":"On March 30, 2023, Vaccinex, Inc. (the “Company”) entered into a stock purchase agreement (the “Stock Purchase Agreement”) pursuant to which the Company agreed to issue and sell 4,975,608 shares of common stock of the Company (the “Shares”) at a purchase price of $0.41 per Share for aggregate gross proceeds of approximately $2.04 million.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1205922/000119312523089004/0001193125-23-089004-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Vaccinex (Rochester), L.L.C. and FCMI Parent Co."},{"label":"Value","value":"aggregate gross proceeds of approximately $2.04 million"},{"label":"Effective","value":"2023-03-30"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}